A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.
Also called NCT07278830
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 214 participants
- Registry
-
NCT07278830
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT07278830. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-02 (actual); primary completion 2024-05-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
- Condition
- Hypercholesterolemia and Mixed Dyslipidemia
- Intervention (Drug)
- SAL003 140mg+Atorvastatin
- Intervention (Drug)
- SAL003 420mg+Atorvastatin
- Intervention (Drug)
- Placebo 140mg+Atorvastatin
- Intervention (Drug)
- Placebo 420mg+Atorvastatin
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Collaborator
- Salubris (Chengdu) Biotechnology Co., Ltd.
Record details
- Record id
cardio:ct-nct07278830- Content hash
3ff6492941aabd44c4b9fde1d69a2328d0fc49c09accf20d31aed46ec7b79ac1